Gefitinib significantly improved outcomes in patients with the EGFR mutation and wild-type PTEN, achieving a progression-free survival (PFS) of approximately 9 months and an overall survival (OS) of about 20 months. Gefitinib demonstrated poorer outcomes in GBM patients with concurrent EGFR and PTEN mutations, with PFS and OS of 6 months and 9 months, respectively [58]. Here, PTEN is linked to glioblastoma.